Vivos Therapeutics (NASDAQ:VVOS) Earns “Buy” Rating from Ascendiant Capital Markets

Vivos Therapeutics (NASDAQ:VVOS)‘s stock had its “buy” rating reiterated by equities researchers at Ascendiant Capital Markets in a research note issued on Wednesday,Benzinga reports. They presently have a $6.60 target price on the stock. Ascendiant Capital Markets’ price objective points to a potential upside of 123.73% from the company’s previous close.

Separately, Alliance Global Partners lowered their price objective on Vivos Therapeutics from $8.25 to $6.00 and set a “buy” rating on the stock in a report on Tuesday.

Vivos Therapeutics Trading Up 2.1 %

Shares of NASDAQ:VVOS opened at $2.95 on Wednesday. The stock has a market capitalization of $14.28 million, a PE ratio of -0.52 and a beta of 7.71. Vivos Therapeutics has a 1 year low of $1.91 and a 1 year high of $48.79. The firm has a fifty day moving average price of $2.78 and a 200 day moving average price of $2.52.

About Vivos Therapeutics

Vivos Therapeutics, Inc, a medical technology company, develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring.